Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Expert consensus perspective on SGLT inhibitor use in type 1 diabetes, outlining mechanisms, trial design recommendations, and safety requirements rather than presenting new clinical trial data.